血清长链非编码RNA MALAT1和AFAP1-AS1与鼻咽癌临床病理特征和预后的关系

doi:10.11904/j.issn.1002-3070.2019.06.007

摘要/Abstract

摘要： 目的探讨血清长链非编码RNA(lncRNA)MALAT1和AFAP1-AS1与鼻咽癌临床病理特征和预后的关系。方法 2013年4月—2015年6月在我院经病理证实的鼻咽癌患者136例为鼻咽癌组,同期选择我院门诊健康体检者54例为对照组,实时荧光逆转录法分析MALAT1和AFAP1-AS1的表达;采用χ²检验分析MALAT1和AFAP1-AS1表达与临床病理特征的关系;Log-rank检验分析血清MALAT1和AFAP1-AS1不同表达水平患者的预后差异。结果与对照组比较,鼻咽癌组MALAT1和AFAP1-AS1表达水平明显升高,差异有统计学意义(P＜0.001);MALAT1和AFAP1-AS1表达与年龄无关(P＞0.05);肿瘤最大径≥5 cm、病理学分期越高、TNM分期越高、浸润深度越深、有淋巴血管间隙浸润、有淋巴结转移、有复发的鼻咽癌患者MALAT1和AFAP1-AS1高表达率升高(P＜0.05);MALAT1和AFAP1-AS1低表达组2年生存率及生存期均明显高于MALAT1和AFAP1-AS1高表达组(P＜0.001);多因素Cox逐步回归分析,结果发现MALAT1低表达(HR=0.52,95% CI:0.37~0.81)和AFAP1-AS1低表达(HR=0.56,95% CI:0.51~0.83)为鼻咽癌患者预后的独立保护因素(P＜0.001)。结论鼻咽癌患者血清lncRNA MALAT1、AFAP1-AS1水平升高,且与鼻咽癌恶性进展有关;鼻咽癌患者血清MALAT1、AFAP1-AS1低表达患者预后良好;MALAT1、AFAP1-AS1可能作为诊断鼻咽癌的新型标志物。

关键词: 血清长链非编码RNA MALAT1, 血清长链非编码AFAP1-AS1, 鼻咽癌, 临床病理特征, 预后

Abstract: Objective The objective of this study was to investigate the relationship between serum long-chain non-coding RNA MALAT1 and AFAP1-AS1 and clinicopathological features,and prognosis of nasopharyngeal carcinoma(NPC).Methods A total of 136 patients with nasopharyngeal carcinoma confirmed by pathology in our hospital were selected from April 2013 to June 2015.During the same time,54 outpatients for health examination in our hospital were selected as the control group and nasopharyngeal carcinoma group.Real-time fluorescence reverse transcription analysis was used to analyze the expression of lncRNA MALAT1 and AFP1-AS1.The relationship between the expression of lncRNA MALAT1 and AFP1-AS1,and clinicopathological characteristics was analyzed by χ² test.Log-rank assay was used to analyze serum long-chain non-coding RNA MALAT1 and prognostic differences in patients with different expression levels of AFAP1-AS1.Results Compared with the control group,the serum levels of RNA MALAT1 and RNA AFAP1-AS1 in the nasopharyngeal carcinoma group were significantly increased(P＜0.001);The expressions of lncRNA MALAT1 and AFAP1-AS1 was not related to age(P＞0.05);The maximum diameter of the tumor was ≥5 cm,the pathological stage was higher,the TNM stage was higher,the deeper in the infiltration depth,the infiltration of lymphatic vessels,the lymph node metastasis,and the recurrence and the higher in high expressive rates of lncRNA MALAT1 and AFAP1-AS1(P＜0.05).The 2-year survival rate and survival time of lncRNA MALAT1 and AFAP1-AS1 in the low expression group were significantly higher than those of the high expression group(P＜0.001);Multivariate Cox stepwise regression analysis showed that low expression of lncRNA MALAT1(HR=0.52,95% CI:0.37~0.81)and low expression of lncRNA AFAP1-AS1(HR=0.56,95% CI:0.51~0.83)were independent prognostic protective factors for NPC patients(P＜0.001).Conclusion The serum long-chain non-coding RNA MALAT1 and AFAP1-AS1 are elevated in patients with NPC,and are positively correlated with malignant progression of NPC.NPC patients with low expression of lncRNA MALAT1 and AFAP1-AS1 serum have a good prognosis;MALAT1 and AFAP1-AS1 can be used as new markers for the diagnosis of nasopharyngeal carcinoma.

Key words: Serum long non-coding RNA MALAT1, Serum long non-coding RNA AFAP1-AS1, Nasopharyngeal carcinoma, Clinicopathological features, Prognosis

中图分类号:

R739.62

刘耿淳, 申良方. 血清长链非编码RNA MALAT1和AFAP1-AS1与鼻咽癌临床病理特征和预后的关系[J]. 实用肿瘤学杂志, 2019, 33(6): 513-518.

LIU Gengchun, SHEN Liangfang. Relationship between serum long-chain non-coding RNA MALAT1 and AFAP1-AS1,and clinicopathological features and prognosis of nasopharyngeal carcinoma[J]. Journal of Practical Oncology, 2019, 33(6): 513-518.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2019.06.007

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2019/V33/I6/513

参考文献

1 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
2 龚巍巍,罗胜兰,费方荣,等.浙江省2005~2010年头颈部恶性肿瘤生存率分析[J].中国肿瘤,2017,26(10):758-761.
3 张攀,张迪,戴晓波.复发鼻咽癌再程放射治疗的研究进展[J].实用肿瘤学杂志,2019,33(1):92-96.
4 刘永刚,闫一敏,杨荣松.血清miRNA复发分子标志物检测与鼻咽癌复发远处转移的相关性[J].实用肿瘤杂志,2018,33(4):354-358.
5 Xiong H,Ni Z,He J,et al.LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cells[J].Oncogene,2017,36(25):3528-3540.
6 Li C,Wang S,Xing Z,et al.A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis[J].Nat Cell Biol,2017,19(2):106-119.
7 Wang Y,Mo Y,Xiang Y,et al.Long non-coding RNA AFAP1-AS1 is a novel biomarker in various cancers:a systematic review and meta-analysis based on the literature and GEO datasets[J].Oncotarget,2017,8(60):102346-102360.
8 Jin Y,Cui Z,Li X,et al.Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer[J].Oncotarget,2017,8(16):26090-26099.
9 Guo D,Ma J,Yan L,et al.Down-regulation of LncRNA MALAT1 attenuates neuronal cell death through suppressing beclin1-dependent autophagy by regulating miR-30a in cerebral ischemic stroke[J].Cell Physiol Biochem,2017,43(1):182-194.
10 Bi S,Wang C,Li Y,et al.lncRNA MALAT1-mediated Axl promotes cell invasion and migration in human neuroblastoma[J].Tumour Biol,2017,39(5):1010428317699796.
11 Zhang ZC,Tang C,Yang D,et al.Targeting lncRNA MALAT1 suppresses the progression of osteosarcoma by altering the expression and localization of β-catenin[J].J Cancer,2018,9(1):71-80.
12 侯婧瑛,凌辉,金小岩,等.lncRNA MALAT1通过靶向下调miR-570-3p促进胃癌细胞增殖[J].中国病理生理杂志,2018,34(12):41-48.
13 Huangfu N,Xu Z,Zheng W,et al.lncRNA MALAT1 regulates oxLDL-induced CD36 expression via activating β-catenin[J].Biochem Biophys Res Commun,2017,495(3):2111-2117.
14 Yi J,Liu D,Xiao J.lncRNA MALAT1 sponges miR-30 to promote osteoblast differentiation of adipose-derived mesenchymal stem cells by promotion of Runx2 expression[J].Cell Tissue Res,2019,376(1):113-121.
15 Feng W,Ni H,Feng S,et al.Overexpression of lncRNA AFAP1-AS1 correlates with poor prognosis and promotes tumorigenesis in colorectal cancer[J].Biomed Pharmacother,2016,81:152-159.
16 Ma F,Wang SH,Cai Q,et al.Overexpression of lncRNA AFAP1-AS1 predicts poor prognosis and promotes cells proliferation and invasion in gallbladder cancer[J].Biomed Pharmacother,2016,84:1249-1255.
17 Feng Y,Zhang Q,Wang J,et al.Increased lncRNA AFAP1-AS1 expression predicts poor prognosis and promotes malignant phenotypes in gastric cancer.[J].Eur Rev Med Pharmacol Sci,2017,21(17):3842-3849.
18 付丛,张行炜.长链非编码RNA AFAP1-AS1在口腔鳞状细胞癌中的表达及临床意义[J].口腔医学研究,2016,32(9):983-986.

[1]	阮鹏, 谭爱丽. 血清中microRNA-127对鼻咽癌患者化疗抗性的预测价值[J]. 实用肿瘤学杂志, 2019, 33(6): 508-512.
[2]	范晋海, 蒋玉梅, 张静, 白晓静. MAP1A在膀胱癌组织中的表达及其与临床病理特征的关系[J]. 实用肿瘤学杂志, 2019, 33(6): 525-530.
[3]	刘四卫, 崔玥, 孙元元, 胡晶, 张文睿, 曹孟儒. FOXD3在肺癌细胞中的作用[J]. 实用肿瘤学杂志, 2019, 33(5): 390-396.
[4]	陈光浩, 方靖萱, 彭素娟, 严炜薇, 王福海, 陈承哲, 陈泗川, 潘建基, 邱素芳. PNCK对鼻咽癌细胞增殖和凋亡作用的研究[J]. 实用肿瘤学杂志, 2019, 33(5): 397-401.
[5]	夏天一, 张博淼, 姚克非, 崔滨滨. PTPN9表达水平与结直肠癌的临床关系研究[J]. 实用肿瘤学杂志, 2019, 33(5): 415-419.
[6]	徐亭, 严斐斐, 张纯慧, 张艳桥. 胃癌骨转移患者临床病理与预后分析[J]. 实用肿瘤学杂志, 2019, 33(5): 436-441.
[7]	李思维 , 庞达. 长链非编码RNA(lncRNA)在癌症中的作用[J]. 实用肿瘤学杂志, 2019, 33(5): 471-475.
[8]	曲雁飞, 刘超, 王勃军, 方琳, 张艳桥. CSN6基因在肝细胞癌组织中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(4): 328-333.
[9]	刘金涛, 高玲, 周会会. MAGEA4和EB1蛋白在肺癌组织中的表达及其与临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(4): 334-339.
[10]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[11]	冯越,邢丽楠,王棹,张云艳. NLR与肿瘤同步放化疗预后的相关性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 284-288.
[12]	白晓斌, 霍龙伟, 谢万福, 徐高峰, 王茂德. Chk1在胶质母细胞瘤中的表达及其与肿瘤生物学行为和预后生存的关联性[J]. 实用肿瘤学杂志, 2019, 33(2): 122-127.
[13]	石小康, 丁佑铭, 汪斌, 余斌, 徐雨. UBE2T在原发性肝癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(2): 128-133.
[14]	卢姣云, 张清媛. 实验室标志物在弥漫大B细胞淋巴瘤预后中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(2): 183-187.
[15]	赵凤娟, 王琪, 任贇虹, 韦珏伶, 黎乐群, 赵新华, 唐娟, 游雪梅. 肝癌伴抑郁患者血清CRP、hs-CRP水平变化及其对预后的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 27-33.